Human Vaccines for Oncogenic Viruses and Perspectives for Tumor Antigens Induced by Virus

Recognition of tumor-associated antigens by T-lymphocytes: perspectives for peptide-based vaccines.

Over the last 10 years, studies of T-cell-mediated responses in vitro have clearly demonstrated that some cancer patients have (mainly but not exclusively) CD8 cytolytic T-lymphocytes (CTL) that can recognize specifically autologous tumor cells [1]. Until 1991, however, no CTL-defined tumor antigen was characterized in molecular terms in humans. With the development of new approaches based on r...

Use of human diploid cell MRC - 5, for production of Measles and Rubella virus vaccines

Overexpressed oncogenic tumor-self antigens

Overexpressed tumor-self antigens represent the largest group of candidate vaccine targets. Those exhibiting a role in oncogenesis may be some of the least studied but perhaps most promising. This review considers this subset of self antigens by highlighting vaccine efforts for some of the better known members and focusing on TPD52, a new promising vaccine target. We shed light on the importanc...

Oncogenic proteins as tumor antigens.

Human immune responses to oncogenic proteins have been reported and are continuing to be defined. Immunity to nonmutated overexpressed oncoproteins as well as to mutated or unique cancer-specific oncoproteins has been identified. Immune system based treatments targeting oncogenic proteins have shown therapeutic efficacy in animals models and are currently being translated into human clinical tr...

Human oncogenic viruses: nature and discovery.

Seven kinds of virus collectively comprise an important cause of cancer, particularly in less developed countries and for people with damaged immune systems. Discovered over the past 54 years, most of these viruses are common infections of humankind for which malignancy is a rare consequence. Various cofactors affect the complex interaction between virus and host and the likelihood of cancer em...